Authors: Halapi, Eva; Hakonarson, Hakon

Source: Current Pharmacogenomics, Volume 3, Number 3, September 2005 , pp. 177-190(14)

Publisher: Bentham Science Publishers

Abstract:

Single nucleotide polymorphisms (SNP) in genes encoding drug receptors, transporters, metabolizing enzymes or DNA repair genes are known to influence the toxicity and efficacy profile of drugs. While the transition of this information to DNA-based tests in order to improve drug selection, identify optimal dosing, maximize drug efficacy or minimize the risk of toxicity has been slow coming, recent advances in molecular biology have yielded new diagnostic assays, some of which have already been incorporated into therapeutic guidelines such as testing for Herceptin protein in breast cancer patients. Moreover, new high-throughput screening methods and data mining approaches have emerged that could revolutionalise the drug development process and reduce the risk of drug failure, while both lowering costs and delivering faster and better results. In this regard, the powerful coupling of linkage to ultra-high throughput genotyping, gene array or proteomics technology, together with innovative bioinformatics resources, provides a focused integrative strategy for pinpointing disease-causing genes that may generate validated drug targets and genes that are responsible for differential drug response. The new information generated has already sparked the initiation of novel strategies and diagnostic approaches in clinical development that are anticipated to ultimately lead to safer and more efficacious drugs.

Keywords: pharmacogenomics; linkage; association; single nucleotide polymorphism; microarray; drug response

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1570160054864012

Affiliations: 1: deCODE genetics, Stugata 1, 101 Reykjavik, Iceland.

Publication date: 2005-09-01

More about this publication?

• Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.
  
  The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Genetics
• By this author: Halapi, Eva ;  Hakonarson, Hakon

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers